Compare Eli Lilly And Co (LLY) vs Sun Life Financial Inc. Common Stock (SLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Sun Life Financial Inc. Common Stock — how do they compare? Eli Lilly And Co trades at $1,226.6 (market cap $1.08T), while Sun Life Financial Inc. Common Stock trades at $77.62 (market cap $43.44B). The key difference: Eli Lilly And Co is far larger — about 24.9× Sun Life Financial Inc. Common Stock's market cap, and Sun Life Financial Inc. Common Stock pays the higher dividend (3.47%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and Sun Life Financial Inc. Common Stock for 0 Days on average.
| LLY | SLF | |
|---|---|---|
Market Cap | $1.08T | $43.44B |
Volume | 2,520,401 | 333,821 |
Sector | Health | Financials |
52-Week High | $1.28K | $84.07 |
52-Week Low | $799.57 | $57.60 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $1.12T | $45.17B |
Dividend Yield | 0.57% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,166.51, down 1.36% on the day, amid strong fundamentals with revenue surging to $65.18B in 2025 and net income reaching $20.64B. The stock exhibits a bullish technical trend, supported by moving averages, with key resistance near $1,190. Recent news highlights promising pipeline developments in weight-loss drugs, reinforcing growth prospects.
Outlook remains positive given robust earnings beats, high analyst buy ratings (73%), and a consensus price target of $1,350. Risks include competitive pressures and execution challenges in scaling production. The stock's premium valuation (P/E 39.16) warrants monitoring, but strong cash flow and innovation pipeline support long-term upside.
Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.
The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Sun Life Financial Inc. Common Stock
Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.
Read more on SLF →
